THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 9, 2005--PharmaFrontiers Corp. (OTCBB:PFTR), a company developing a novel cell therapy for multiple sclerosis, which is about to enter Phase IIb clinical trials, announced today that it has retained MDB Capital Group to serve as its financial advisor.
